Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fluzone Quadrivalent

- PMLiVE

Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Dupixent is the first and only drug specifically recommended for EoE in the US

- PMLiVE

Sanofi launches new funding foundation

Foundation S is a philanthropic endowment fund aimed at encouraging healthier lives for future generations

- PMLiVE

Sanofi and McLaren Racing come together to maximise performance and operational excellence

The partnership will complement Sanofi’s R&D pipeline, which has 25 new launches planned over the next five years

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

Sanofi launches Diversity, Equity & Inclusion Board

The Board is the first of its kind in the pharma industry to have outside advisors

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis

The results were announced at the American Academy of Dermatology 2022 Annual Meeting

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for Dupixent

The trial involved patients with eosinophilic oesophagitis, an inflammatory disease that damages the oesophagus and makes eating and drinking painful

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links